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I. Bernard Weinstein
September 9, 1930–November 3, 2008The sudden death of Dr. I. Bernard Wein-
stein on November 3, 2008, left all who
knew him shocked and saddened. He had
spoken to colleagues just days earlier, as
usual discussing the latest results from his
lab and new ideas. The community has
lost a most dear colleague and mentor,
and a leader who paved major roads in
cancer research.
Bernie was born in Madison, Wiscon-
sin, the youngest of four sons of Russian
immigrants who inspired in him a lifelong
dedication to learning and intellectual pur-
suit. He completed his bachelor’s and
medical degrees at the University of Wis-
consin and his residency at Montefiore
Hospital in New York. Early in his career,
Bernie discovered a passion for research,
initially as a clinical associate at the
National Cancer Institute (NCI) and later
as a fellow at Harvard Medical School
and MIT. Bernie was recruited to Colum-
bia University in 1961 and was an active
member of the Columbia faculty as a Pro-
fessor and Attending Physician until his
death. Bernie’s passion for research dis-
tinguished him throughout his career,
even as he assumed major administrative
roles, including Director of the Environ-
mental Health Sciences Division at the
Columbia School of Public Health, Direc-
tor of the Columbia-Presbyterian Com-
prehensive Cancer Center, and President
of the American Association for Cancer
Research (AACR). Bernie’s contributions
to cancer research broke new ground
in our understanding of the mechanisms
of multistage carcinogenesis and laid
the foundation for additional discoveries
based on the concepts he first articulated.
Here we summarize some of his major
accomplishments.
Beginning in the 1970s, Bernie (often in
collaboration with his close friend Dezider
Grunberger) identified the structures of
covalent adducts formed by chemical
carcinogens on DNA and how such mod-
ifications altered the conformation of the
DNA helix. In the case of BPDE, the reac-
tive metabolite of the polycyclic aromatic
hydrocarbon benzo(a)pyrene, the bulky
carcinogen residue binds the N2 position
of guanine and lies in the minor grooveof the double helix. In contrast, the acti-
vated form of the carcinogenic aromatic
amine N-2-acetylaminofluorene binds the
C8 position of guanine, causing the mod-
ified base to be displaced from the helix
and inducing a major distortion of DNA
structure. Bernie’s research identified
conformational changes elicited by car-
cinogens bound to DNA and provided
insight into the mutagenicity of such com-
pounds. As a result, today it is well recog-
nized that such changes underlie some of
the mutations observed in oncogenes and
tumor suppressor genes. Furthermore,
the discovery that DNA conformation is
altered due to adduct formation led to the
idea that it could be possible to monitor
DNA adducts as an approach to assess-
ing exposure to, and biologically effective
doses of, carcinogens. In collaboration
with the groups of Stuart Yuspa and Cur-
tis Harris at NCI, Bernie developed im-
munoassays to detect carcinogen-DNA
adduct formation in human tissues follow-
ing carcinogen exposure. These studies
blazed a trail to a new field in cancer re-
search, termed molecular epidemiology,
and set the foundation for the ability to
identify populations at increased risk of
cancer by analyzing specific markers as-
sociated with environmental exposures.Cancer Cell 14Bernie also pioneered studies of the
molecular actions of tumor promoters,
compounds that lack carcinogenic capac-
ity on their own but promote tumor forma-
tion from cells initiated by subthreshold
doses of carcinogens. His group was the
first to define molecular responses in cells
treated with the phorbol ester tumor pro-
moter TPA. He also showed that transfor-
mation of rodent cells by oncogenes is
enhanced by treatment with TPA. Follow-
ing the identification of protein kinase C
(PKC) asa phorbol ester receptorbyCasta-
gna and Nishizuka, Bernie’s lab character-
izedbiochemical interactionsbetweenTPA
and PKC and demonstrated thatPKC bind-
ing and activation are common properties
of diverse, structurally unrelated tumor
promoters. His group was one of several
to clone cDNAs encoding PKC and show
that PKC constitutes a family of related
enzymes. Importantly,Bernie’s lab showed
that enhanced expression of specific PKC
isoforms mimics the effects of TPA, provid-
ing evidence that PKC is the key mediator
of phorbol ester-induced tumor promotion.
Finally, following studies in his and other
labs on deregulated expression of cell-
cycle control proteins in cancer cells,
Bernie proposed concepts about homeo-
static feedback mechanisms in tumor
cells that have worn well with time, gaining
wide attention. In 2000, he proposed that
multiple oncoproteins and tumor suppres-
sors interact in complex networks analo-
gous to electronic circuits and that accu-
mulation of multiple mutations in cancer
cells leads to disordered, or even ‘‘bi-
zarre,’’ types of circuitry not present in
the normal parental cells. Bernie thus pos-
tulated that specific key proteins in cancer
cells function within contexts not found in
normal cells. Accordingly, he suggested
that the regulatory circuitry operating in
evolving tumor cell populations must
adapt to the stochastic occurrence of
additional mutations, possibly through
homeostatic feedback mechanisms. In
2002, Bernie coined the term ‘‘oncogene
addiction’’ and elaborated on the concept
that even though cancer cells harbor
numerous genetic and epigenetic alter-
ations, many are dependent on a single, December 9, 2008 ª2008 Elsevier Inc. 421
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their malignant phenotype and, often, their
survival; by contrast, normal cells do not
exhibit such dependency. He suggested
that the phenomenon of oncogene addic-
tion reflects the notion that the multistage
process of carcinogenesis involves disor-
dered regulatory circuitry, which arises in
tumors as a consequence of oncogene
activation and tumor suppressor gene in-
activation events. Bernie’s concept of on-
cogene addiction could in fact serve as an
‘‘Achilles’ heel’’ for cancer cells and sug-
gests therapies targeted at single path-
ways, which spare normal cells. Recent
clinical successes with chronic myeloge-
nous leukemia and with a subset of non-
small cell lung cancers that harbor specific
mutations of the EGF receptor augur well
for this approach.
Bernie authored more than 600 publica-
tions, and his accomplishments were422 Cancer Cell 14, December 9 2008 ª2008recognized by numerous honors, among
them the Clowes Award from the AACR,
the Anthony Dipple Carcinogenesis
Award, the Distinguished Achievement
Award of the American Society of Preven-
tive Oncology, the AACR-American Can-
cer Society Award for Excellence in Cancer
Epidemiology and Prevention, the Charles
Heidelberger Award for Cancer Research,
and an honorary degree from his alma
mater, the University of Wisconsin. He
was a member of the Institute of Medicine
and a fellow of the American Association
for the Advancement of Science and the
American Academy of Arts and Sciences.
Bernie is survived by his wife of 56
years, Joan; their three children; two
grandchildren; and a large extended fam-
ily. He is also survived by a large group of
students, postdocs, and other trainees
whom he—and we—considered his sec-
ond family. When referring to those whoElsevier Inc.inspired him, Bernie often cited the 12th-
century Hebrew scholar and physician
Maimonides, who said ‘‘Honor your
teachers, because they have brought
you into the world of the future.’’ Bernie in-
spired those he taught to emulate not only
his qualities of creativity and excellence in
science but also his personal qualities of
warmth, generosity, and integrity. He will
be sorely missed.
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